The growth factor receptor FGFR3 increases the rate of growth and aggressiveness of hepatocellular carcinomas especially liver cell cancer. Inhibition of this receptor could be a new and effective way of treating patients. In a recent study, scientists from the Institute for Cancer Research at Med Uni Vienna have shown that the growth factor receptor FGFR3 increases the rate of growth and aggressiveness of hepatocellular carcinomas (liver cell cancer). Inhibition of this receptor could be a new and effective way of treating patients.
The paper has now been published in the top-ranking journal, Hepatology. Hepatocellular carcinoma (or HCC) is the commonest form of liver cancer and is regarded as one of the most aggressive tumours in the world. Approximately 6% of all cancers in men and around 3% of all cancers in women are hepatocellular carcinomas. It is one of the most frequent causes…
